Literature DB >> 25400822

Dysregulation of JAM-A plays an important role in human tumor progression.

Chen Zhao1, Funian Lu1, Hongxia Chen1, Xianda Zhao1, Jun Sun2, Honglei Chen1.   

Abstract

Junctional adhesion molecule A (JAM-A) is a transmembrane protein that belongs to the immunoglobulin (Ig) superfamily. Evidence determines that JAM-A plays a role in numerous cellular processes, including tight junction assembly, leukocyte migration, platelet activation, angiogenesis and virus binding. Recent research suggests that JAM-A is dysregulated in various cancers and is vital for tumor progression. JAM-A is implicated in carcinogenesis via different signal pathways such as TGF-β1 signaling. Furthermore, JAM-A expression in cancers is usually associated with certain outcome of patients and might be a prognostic indicator. In this review, the correlation between JAM-A expression and human cancers will be described.

Entities:  

Keywords:  Tight junction; junctional adhesion molecule-A; tumor progression

Mesh：

Substances：

Year:  2014        PMID： 25400822      PMCID： PMC4230059     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


  37 in total

1.  Deletion of JAM-A causes morphological defects in the corneal epithelium.

Authors:  Liang I Kang; Yan Wang; Arthur T Suckow; Kirk J Czymmek; Vesselina G Cooke; Ulhas P Naik; Melinda K Duncan
Journal:  Int J Biochem Cell Biol       Date:  2006-10-28       Impact factor: 5.085

Review 2.  The JAM family of proteins.

Authors:  Kenneth J Mandell; Charles A Parkos
Journal:  Adv Drug Deliv Rev       Date:  2005-04-25       Impact factor: 15.470

Review 3.  Loss of tight junction barrier function and its role in cancer metastasis.

Authors:  Tracey A Martin; Wen G Jiang
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 4.  Alterations in the establishment and maintenance of epithelial cell polarity as a basis for disease processes.

Authors:  B A Molitoris; W J Nelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

5.  Junctional adhesion molecules are required for melanoma cell lines transendothelial migration in vitro.

Authors:  Stephanie Ghislin; Dorian Obino; Sandrine Middendorp; Nicole Boggetto; Catherine Alcaide-Loridan; Frederique Deshayes
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-28       Impact factor: 4.693

6.  Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.

Authors:  K Brennan; E A McSherry; L Hudson; E W Kay; A D K Hill; L S Young; A M Hopkins
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

Review 7.  The role of junctional adhesion molecules in vascular inflammation.

Authors:  Christian Weber; Line Fraemohs; Elisabetta Dejana
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

8.  Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma.

Authors:  Paul Gutwein; Anja Schramme; Beren Voss; Mohamed Sadek Abdel-Bakky; Kai Doberstein; Andreas Ludwig; Peter Altevogt; Martin-Leo Hansmann; Holger Moch; Glen Kristiansen; Josef Pfeilschifter
Journal:  Biochem Biophys Res Commun       Date:  2009-01-23       Impact factor: 3.575

9.  Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression.

Authors:  Min Zhang; Wenting Luo; Bo Huang; Zihui Liu; Limei Sun; Qingfu Zhang; Xueshan Qiu; Ke Xu; Enhua Wang
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

Review 10.  Tight junction-related human diseases.

Authors:  Norimasa Sawada
Journal:  Pathol Int       Date:  2013-01-07       Impact factor: 2.534
View more
  18 in total

1.  Breast Tumor-Associated Metalloproteases Restrict Reovirus Oncolysis by Cleaving the σ1 Cell Attachment Protein and Can Be Overcome by Mutation of σ1.

Authors:  Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa.

Authors:  Laudine Communal; Mauricio Medrano; Fabrice Sircoulomb; Joshua Paterson; Martin Köbel; Kurosh Rahimi; Paul Hoskins; Dongsheng Tu; Stephanie Lheureux; Amit Oza; Laurie Ailles; Diane Provencher; Robert Rottapel; Anne-Marie Mes-Masson
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

3.  Investigation of JAM-A (rs790056) and LFA-1 (rs8058823) gene variants in Turkish colorectal cancer patients.

Authors:  Burcu Çaykara; Hani Alsaadoni; Halime Hanım Pençe; Sadrettin Pençe; Hülya Yılmaz Aydoğan; Didem Taştekin
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

4.  JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.

Authors:  Peng-Peng Xu; Yi-Feng Sun; Ying Fang; Qi Song; Zi-Xun Yan; Yi Chen; Xu-Feng Jiang; Xiao-Chun Fei; Yan Zhao; Christophe Leboeuf; Biao Li; Chao-Fu Wang; Anne Janin; Li Wang; Wei-Li Zhao
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

5.  JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.

Authors:  A G Solimando; A Brandl; K Mattenheimer; C Graf; M Ritz; A Ruckdeschel; T Stühmer; Z Mokhtari; M Rudelius; J Dotterweich; M Bittrich; V Desantis; R Ebert; P Trerotoli; M A Frassanito; A Rosenwald; A Vacca; H Einsele; F Jakob; A Beilhack
Journal:  Leukemia       Date:  2017-09-28       Impact factor: 11.528

Review 6.  miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.

Authors:  Yue Teng; Xuan Su; Xing Zhang; Yan Zhang; Chen Li; Wenquan Niu; Chang Liu; Kai Qu
Journal:  Oncotarget       Date:  2016-12-06

Review 7.  Tight junction proteins in gastrointestinal and liver disease.

Authors:  Mirjam B Zeisel; Punita Dhawan; Thomas F Baumert
Journal:  Gut       Date:  2018-10-08       Impact factor: 31.793

8.  Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models.

Authors:  Arjanneke F van de Merbel; Geertje van der Horst; Maaike H van der Mark; Selas T F Bots; Diana J M van den Wollenberg; Corrina M A de Ridder; Debra Stuurman; Tilly Aalders; Sigrun Erkens-Schulz; Nadine van Montfoort; Wouter R Karthaus; Niven Mehra; Minke Smits; Jack A Schalken; Wytske M van Weerden; Rob C Hoeben; Gabri van der Pluijm
Journal:  Cancer Gene Ther       Date:  2021-06-16       Impact factor: 5.854

Review 9.  Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.

Authors:  Adil Mohamed; Randal N Johnston; Maya Shmulevitz
Journal:  Viruses       Date:  2015-12-01       Impact factor: 5.048

10.  Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells.

Authors:  Ying Shi; Xiao-Xiao Huang; Guo-Bin Chen; Ying Wang; Qiang Zhi; Yuan-Sheng Liu; Xiao-Ling Wu; Li-Fen Wang; Bing Yang; Chuan-Xing Xiao; Hui-Qin Xing; Jian-Lin Ren; Yin Xia; Bayasi Guleng
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.